Prognostic value of urokinase-type plasminogen activator (UPA) and its inhibitor PAI-1 in breast cancer

1993 ◽  
Vol 29 ◽  
pp. S31
Author(s):  
M. Schmitt ◽  
F. Jänicke ◽  
C. Thomssen ◽  
L. Pache ◽  
J. Bläser ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Plasminogen Activator ◽  
Prognostic Value ◽  
Type Plasminogen Activator ◽  
Urokinase Type Plasminogen Activator ◽  
Pai 1

scholarly journals Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer

1999 ◽  
Vol 80 (1-2) ◽  
pp. 286-294 ◽  
Author(s):  
J H de Witte ◽  
C G J Sweep ◽  
J G M Klijn ◽  
N Grebenschikov ◽  
H A Peters ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Plasminogen Activator ◽  
Prognostic Value ◽  
Tissue Type ◽  
Tissue Type Plasminogen Activator ◽  
Type Plasminogen Activator ◽  
Pai 1

Urokinase-type plasminogen activator: a potent marker of metastatic potential in human cancers

2002 ◽  
Vol 30 (2) ◽  
pp. 207-210 ◽  
Author(s):  
M. J. Duffy
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Plasminogen Activator ◽  
Prospective Trial ◽  
Axillary Node ◽  
Prognostic Impact ◽  
Breast Cancer Patients ◽  
Type Plasminogen Activator ◽  
Urokinase Type Plasminogen Activator ◽  
Pai 1

Urokinase-type plasminogen activator (uPA) is a serine protease that is causally involved in cancer progression, especially invasion and metastasis. Multiple studies have shown that breast cancer patients whose primary cancer contains high levels of uPA have a significantly worse outcome than patients with low levels. As a prognostic marker for breast cancer the information supplied by uPA is both independent of traditionally used factors and significant in the important subgroup of axillary-node patients. Paradoxically, high levels of plasminogen activator inhibitor-1 (PAI-1), an endogenous inhibitor of uPA, also predict for aggressive disease. Recently, the prognostic impact of both uPA and PAI-1 in axillary node-negative breast cancer was confirmed using two different Level 1 Evidence studies, i.e. in both a randomized prospective trial and a pooled analysis. Therefore, uPA and PAI-1 appear to have fulfilled all the criteria for the routine assessment of prognosis in newly diagnosed breast cancer patients

Sign in / Sign up

Export Citation Format

Share Document